LP 261
Alternative Names: LP-261Latest Information Update: 16 Jul 2016
At a glance
- Originator Locus Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO)
- 16 Apr 2008 Interim pharmacokinetics data from a phase I trial in Solid tumours presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
- 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section